<DOC>
	<DOCNO>NCT00506129</DOCNO>
	<brief_summary>The goal clinical research study see receive transplant blood stem cell ( cell produce blood ) bone marrow either relate donor ( brother , sister relative ) unrelated voluntary donor help patient advance cutaneous T-cell lymphoma . The length time patient receive treatment remain free disease also study .</brief_summary>
	<brief_title>Allogeneic Transplantation Patients With Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description>You receive chemotherapy drug fludarabine 5 day ( Days 1 5 ) . The drug melphalan give Days 4 5 . You may also receive drug anti-thymocyte globulin ( ATG ) Days 4 , 5 , 6 . This follow infusion blood stem cell bone marrow donor Day 7 . A separate consent provide donor . The donor brother , sister another family member compatible unrelated donor . The drug stem cell give catheter ( small tube ) place collarbone . You may receive treatment inpatient outpatient basis . If treat inpatient basis , stay hospital treatment recovery , take 4 5 week even complication . The chemotherapy ATG give help body accept transplanted stem cell bone marrow . You receive antibiotic fight infection medicine call G-CSF ( NeupogenÂ® ) help blood count rise back healthier level . G-CSF give injection skin . You also need blood platelet transfusion . You give standard drug help decrease risk side effect . You may ask study staff information drug give risk . If cancer grow graft-versus-host disease present , may eligible receive donor blood cell ( lymphocyte ) infuse catheter . This may cause graft-versus-host disease may help shrink cancer . If cancer grow graft-versus-host disease already present , donor lymphocyte give . Sometimes , body reject donor cell ; reaction call `` graft rejection '' . Sometimes donor cell attack body , reaction call graft-versus-host disease ( GvHD ) . The drug tacrolimus methotrexate give help prevent reaction occur . These drug give vein mouth and/or transplant . You must stay Houston area least 100 day transplant . After 100 day , must return Houston every 3 month 2 year test checkup , year least 3 year . If sign lymphoma growth follow visit ( ) , receive treatment . This investigational study . The drug use study approve FDA commercially available . As many 35 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients pathologically proven CTCL , disease stage IIB IVB , patient must least PR ( skin lymph node ) receive nonallogeneic transplant therapy , age &lt; /= 70 year , Zubrod performance status 0 1 , leave ventricular ejection fraction &gt; /= 50 % approve transplant cardiologist , DLCO &gt; /= 50 % predict approved transplant pulmonologist , serum creatinine &lt; /= 1.5 mg/dL , serum bilirubin &lt; 2mg/dL . SGPT &lt; 3 x upper limit normal , previous history allogeneic transplantation . 2 . Donor : HLAcompatible related ( HLAA , B , DRB1 match oneantigen mismatch ) HLAcompatible unrelated ( HLAA , B , C DRB1 match oneantigen mismatch ) . 1 ) Patients active CNS disease .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Cutaneous T-Cell Lymphoma</keyword>
	<keyword>CTCL</keyword>
	<keyword>Allogeneic Transplantation</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Allogeneic peripheral blood progenitor cell</keyword>
	<keyword>PBPC</keyword>
	<keyword>Bone Marrow transplantation</keyword>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>SCT</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Melphalan</keyword>
</DOC>